Regulation of medical devices in Northern Ireland

AI Summary

This guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) outlines the regulatory framework for medical devices and in vitro diagnostic (IVD) devices in Northern Ireland under the Windsor Framework. Following the implementation of EU MDR (2017/745) on May 26, 2021, and IVDR (2017/746) on May 26, 2022, the Medical Devices Amendment Regulations 2024 (effective March 21, 2024) introduced specific enforcement provisions for Northern Ireland. The primary focus is ensuring that devices meet EU safety standards while maintaining market access between Northern Ireland and Great Britain. Main violations and compliance issues identified include failure to meet safety requirements, incorrect risk classification, and lack of proper technical documentation, which can lead to criminal penalties, including fines or imprisonment. Required actions for manufacturers include obtaining CE marking (or combined CE and UK(NI) marking if using a UK-based notified body), designating a Northern Ireland or EU-based authorized representative for GB-based companies, and registering as 'Actors' in the EUDAMED database by May 28, 2026. Furthermore, manufacturers must notify the MHRA of any supply interruptions at least six months in advance if such disruptions risk patient harm. Importers and distributors are also tasked with verifying conformity declarations and maintaining rigorous complaint and recall registries.